Literature DB >> 28972867

A National Analysis of Medicaid Home and Community Based Services Waivers for People With Intellectual and Developmental Disabilities: FY 2015.

Carli Friedman1.   

Abstract

Medicaid Home and Community Based Services (HCBS) 1915(c) waivers are the largest source of funding for the long term services and supports of people with intellectual and developmental disabilities (IDD). National-level analyses of HCBS IDD waivers are crucial because of the large variance across states, the recent CMS rule and regulation changes (CMS 2249-F/2296-F), and the ever changing economic and political landscape. Therefore, the aim of this study was to examine state waiver priorities for people with IDD. In FY 2015, 111 waivers projected spending $25.6 billion for approximately 630,000 people with IDD. The services with the most funding were residential habilitation, supports to live in one's own home, and day habilitation. However, our analysis revealed large discrepancies across states and services.

Entities:  

Keywords:  Medicaid Home and Community Based Services 1915(c) waivers; community living; intellectual and developmental disabilities; public policy

Mesh:

Year:  2017        PMID: 28972867     DOI: 10.1352/1934-9556-55.5.281

Source DB:  PubMed          Journal:  Intellect Dev Disabil        ISSN: 1934-9491


  3 in total

1.  Occupational Therapy in Medicaid Home and Community-Based Services Waivers.

Authors:  Carli Friedman; Laura VanPuymbrouck
Journal:  Am J Occup Ther       Date:  2018 Mar/Apr

2.  Key stakeholder perspectives on obstacles to an autism-specific Medicaid waiver service delivery model.

Authors:  Calliope Holingue; Yeon Jang; Gazi Azad; Rebecca Landa
Journal:  J Appl Res Intellect Disabil       Date:  2021-09-23

3.  Therapy use for U.S. school-aged children with developmental disabilities: State variation and determinants.

Authors:  Olivia Lindly; Megan C Eaves; Yue Xu; Chelsey L Tarazi; Sowmya R Rao; Karen A Kuhlthau
Journal:  Disabil Health J       Date:  2021-08-28       Impact factor: 2.554

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.